VXM01 phase I study in patients with resectable progression of a glioblastoma.

Wolfgang Wick(Hertie Institute for Clinical Brain Research), Michael Platten(National Center for Tumor Diseases), Marlene Arzt(Heidelberg University), Martin Bendszus(Heidelberg University), David Bonekamp(Heidelberg University), Sébastien Wieckowski(Centre National de la Recherche Scientifique), Christel Herold‐Mende, Heinz Lubenau(Vaximm (Germany)), Philipp Kickingereder(Heidelberg University), Dennis Riehl(European Molecular Biology Organization), Antje Wick(Heidelberg University), Andreas von Deimling(Heidelberg University), Felix Sahm(German Cancer Research Center), Philipp Beckhove(University Hospital Regensburg), Christine Jungk, Andreas Unterberg(Humboldt-Universität zu Berlin), Friedrich H. Schmitz-Winnenthal(Klinikum Aschaffenburg), Martha Nowosielski(Innsbruck Medical University)
Journal of Clinical Oncology
May 20, 2017
Cited by 4


Related Papers